The unique characteristics of MPO and EPO (rapid cidal action, broad-spectrum
activity, and unique mechanism of action) are especially well-suited for
preventing and treating the most serious types of nosocomial infections.
The incidence of nosocomial (or hospital-acquired) infections is estimated
at 2 million cases annually, with 50% - 60% of those cases caused by antibiotic-resistant
pathogens. The costs of nosocomial infections in the US are estimated
at close to $6 billion annually with treatment costs for antibiotic-resistant
nosocomial infections alone estimated at $1.3 billion dollars.
Incidence and resistant infections increase
Nosocomial infections, including surgical site infections, urinary tract
infections, and ventilator-associated pneumonia, are increasing due to
the aging of the population and treatment of older and more immunocompromised
patients in hospital settings.
These infections are caused by a changing profile of pathogens, which
are becoming increasingly resistant to available drugs. While bacterial
resistance is the major threat, viral and fungal resistance is expected
to become more important. Few, if any, drugs are available to effectively
address these rapidly emerging problems. The Exoxemis MPO technology platform
offers an alternative to traditional methods of preventing nosocomial
infection without contributing to antimicrobial